This page shows the latest Lixiana news and features for those working in and with pharma, biotech and healthcare.
Other directly-acting or ‘novel orally acting anticoagulants’ (NOACs) include Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa – which like Eliquis are Factor Xa inhibitors – and Boehringer
More notably, Lixiana users are far less likely to promote the drug than Xarelto or Pradaxa users, despite having a similar level of confidence in the drug as Xarelto users and ... Are Lixiana users missing the confidence that Xarelto and Eliquis users
Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.
Daiichi Sankyo is looking to new products such as novel oral anticoagulant (NOAC) Lixiana (edoxaban) - as well as pipeline candidates like tivantinib for liver cancer, quizartinib for leukaemia and mirogabalin for
The company is hoping that newer products such as novel oral anticoagulant (NOAC) Savaysa/Lixiana (edoxaban) will eventually fill the void left by Benicar, which is facing a challenging start as
The Japanese drugmaker is already a major player in the thrombosis market with products such as Eli Lilly-partnered antiplatelet drug Effient (prasugrel) and recently-introduced NOAC Lixiana (edoxaban).
More from news
Approximately 3 fully matching, plus 13 partially matching documents found.
trial. Edoxaban. Edoxaban (Lixiana; Daiichi Sankyo) is an oral, once-daily, selective factor Xa inhibitor approved in Japan for prevention of VTE following major orthopaedic surgery.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...